These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 36077708)

  • 1. Targeting CD38 in Neoplasms and Non-Cancer Diseases.
    Szlasa W; Czarny J; Sauer N; Rakoczy K; Szymańska N; Stecko J; Kołodziej M; Kaźmierczak M; Barg E
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers.
    Jiao Y; Yi M; Xu L; Chu Q; Yan Y; Luo S; Wu K
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1295-1308. PubMed ID: 32822558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CD38 targeted treatment for multiple myeloma].
    Jelínek T; Mihályová J; Hájek R
    Vnitr Lek; 2018; 64(10):939-948. PubMed ID: 30590941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
    Kassem S; Diallo BK; El-Murr N; Carrié N; Tang A; Fournier A; Bonnevaux H; Nicolazzi C; Cuisinier M; Arnould I; Sidhu SS; Corre J; Avet-Loiseau H; Teillaud JL; van de Velde H; Wiederschain D; Chiron M; Martinet L; Virone-Oddos A
    Blood; 2022 Feb; 139(8):1160-1176. PubMed ID: 35201323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
    Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
    Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
    [No Abstract]   [Full Text] [Related]  

  • 6. CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
    Frerichs KA; Nagy NA; Lindenbergh PL; Bosman P; Marin Soto J; Broekmans M; Groen RWJ; Themeli M; Nieuwenhuis L; Stege C; Nijhof IS; Mutis T; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Expert Rev Clin Immunol; 2018 Mar; 14(3):197-206. PubMed ID: 29465271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
    van de Donk NW; Janmaat ML; Mutis T; Lammerts van Bueren JJ; Ahmadi T; Sasser AK; Lokhorst HM; Parren PW
    Immunol Rev; 2016 Mar; 270(1):95-112. PubMed ID: 26864107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.
    Franssen LE; Stege CAM; Zweegman S; van de Donk NWCJ; Nijhof IS
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32331242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding anti-CD38 immunotherapy for lymphoid malignancies.
    Wang X; Yu X; Li W; Neeli P; Liu M; Li L; Zhang M; Fang X; Young KH; Li Y
    J Exp Clin Cancer Res; 2022 Jun; 41(1):210. PubMed ID: 35765110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reprint of "Immunomodulatory effects of CD38-targeting antibodies".
    van de Donk NWCJ
    Immunol Lett; 2019 Jan; 205():71-77. PubMed ID: 30826127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy.
    Calabretta E; Carlo-Stella C
    Cells; 2020 Mar; 9(4):. PubMed ID: 32225002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.
    Seckinger A; Hillengass J; Emde M; Beck S; Kimmich C; Dittrich T; Hundemer M; Jauch A; Hegenbart U; Raab MS; Ho AD; Schönland S; Hose D
    Front Immunol; 2018; 9():1676. PubMed ID: 30079070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CD38
    Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
    Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
    Roccatello D; Fenoglio R; Sciascia S; Naretto C; Rossi D; Ferro M; Barreca A; Malavasi F; Baldovino S
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isatuximab for the treatment of multiple myeloma.
    Goldsmith SR; Liu L; Covut F
    Drugs Today (Barc); 2021 Nov; 57(11):665-675. PubMed ID: 34821880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
    Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
    Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD38 antibodies in multiple myeloma: back to the future.
    van de Donk NWCJ; Richardson PG; Malavasi F
    Blood; 2018 Jan; 131(1):13-29. PubMed ID: 29118010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
    Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
    Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.